These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 611842)

  • 21. [Aluminum hydroxide treatment of hyperphosphatemia in uremia].
    Bergquist-Poppen M; Bergström J; Wallin R
    Lakartidningen; 1972 May; 69(19):2319-20. PubMed ID: 5035811
    [No Abstract]   [Full Text] [Related]  

  • 22. 1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialyzed patients taking Al(OH)3.
    Demontis R; Westeel PF; Boudalliez B; Moriniere P; Leflon A; Abdulmassih Z; Atik H; Renaud H; Fournier A
    Kidney Int Suppl; 1988 Mar; 24():S175-7. PubMed ID: 3163043
    [No Abstract]   [Full Text] [Related]  

  • 23. [Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era].
    Arenas MD; Malek T; Gil MT; Moledous A; Núñez C; Alvarez-Ude F
    Nefrologia; 2008; 28(2):168-73. PubMed ID: 18454706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia.
    Fournier A; Moriniere P; Sebert JL; Dkhissi H; Atik A; Leflon P; Renaud H; Gueris J; Gregoire I; Idrissi A
    Kidney Int Suppl; 1986 Feb; 18():S114-9. PubMed ID: 3457987
    [No Abstract]   [Full Text] [Related]  

  • 25. Calcium acetate used as phosphate binding treatment in uremic hyperphosphatemia.
    Wikström B; Danielson BG; Fellström B
    Adv Perit Dial; 1991; 7():221-4. PubMed ID: 1680430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What treatment would you advise for a 1-year-old child with chronic renal failure who has been on aluminum hydroxide as a phosphate binder for 6 months and then develops epilepsy and is found to have a grossly raised plasma aluminum concentration?
    Andreoli SP; Chesney RW; Salusky IB; Sedman AB
    Pediatr Nephrol; 1990 Jul; 4(4):318. PubMed ID: 2206897
    [No Abstract]   [Full Text] [Related]  

  • 27. Phosphate and pepsin adsorptions by a new boehmite compound and aluminum hydroxide.
    Nishida M; Yoshimura Y; Kawada J; Ookubo A; Kagawa T; Ikawa A; Hashimura Y; Suzuki T
    Biochem Int; 1990 Dec; 22(5):913-20. PubMed ID: 2099151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Aluminum: a light metal or a dangerous poison?].
    de Wolff FA
    Ned Tijdschr Geneeskd; 1985 Jan; 129(2):52-3. PubMed ID: 3969170
    [No Abstract]   [Full Text] [Related]  

  • 29. [Aluminum poisoning: analysis of a key decade in the knowledge of the biological effects of this element].
    Cannata Andía JB
    Rev Clin Esp; 1989 Apr; 184(7):371-5. PubMed ID: 2505339
    [No Abstract]   [Full Text] [Related]  

  • 30. [Aluminum and magnesium burden of dialysis patients using antacids. A comparative study].
    Eichhorn M
    Fortschr Med; 1989 Aug; 107(23):502-6. PubMed ID: 2670719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcium alginate, an aluminum-free phosphate binder, in patients on CAPD.
    Passlick J; Wilhelm M; Busch T; Grabensee B; Ohnesorge FK
    Clin Nephrol; 1989 Aug; 32(2):96-100. PubMed ID: 2766587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Osteomalacia from phosphate-binding substances (author's transl)].
    Emanuelli C; Borghi M; Pecchini F
    Ateneo Parmense Acta Biomed; 1975; 46(6):577-87. PubMed ID: 1222067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cerebral atrophy: an emerging complication in uremic patients].
    Savazzi GM; Allegri L; Bocchi B; Garini G; Borghetti A
    Ann Ital Med Int; 1987; 2(4):299-307. PubMed ID: 3079453
    [No Abstract]   [Full Text] [Related]  

  • 34. [Serum aluminum in hemodialysis patients. Relation to osteodystrophy, encephalopathy and aluminum hydroxide consumption].
    Nielsen LP; Heaf JG
    Ugeskr Laeger; 1983 May; 145(18):1363-7. PubMed ID: 6868163
    [No Abstract]   [Full Text] [Related]  

  • 35. The continuous challenge of cardiovascular and bone and bone disease in uremic patients: clinical consequences of hyperphosphatemia and advanced therapeutic approaches.
    Brancaccio D; Zoccali C
    J Nephrol; 2006; 19(1):12-20. PubMed ID: 16523420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aluminum-free intestinal phosphate binding.
    Schneider H; Kulbe KD; Weber H; Streicher E
    Contrib Nephrol; 1984; 38():32-6. PubMed ID: 6713898
    [No Abstract]   [Full Text] [Related]  

  • 37. [Is aluminum poisoning unavoidable in the uremic patient?].
    Drüeke T; Rottembourg J
    Nephrologie; 1985; 6(5):217-8. PubMed ID: 4094634
    [No Abstract]   [Full Text] [Related]  

  • 38. [Aluminum poisoning].
    Cervar M; Stavljenic A; Vukicević S
    Lijec Vjesn; 1989; 111(4-5):164-9. PubMed ID: 2671563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of aluminum toxicity in infantile uremia with deferoxamine.
    Freundlich M; Zilleruelo G; Faugere MC; Abitbol C; Strauss J; Malluche HH
    J Pediatr; 1986 Jul; 109(1):140-3. PubMed ID: 3723235
    [No Abstract]   [Full Text] [Related]  

  • 40. Prophylactic aluminium hydroxide and hyperaluminaemia in intensive care.
    Mackway-Jones K; Cove-Smith R; Lawler P
    Intensive Care Med; 1987; 13(4):293-4. PubMed ID: 3497185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.